New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
06:37 EDTALXNAlexion granted ODD to Soliris by FDA
Alexion Pharmaceuticals announced that the FDA has granted an orphan drug designation, or ODD, to Soliris, a first-in-class terminal complement inhibitor, for the prevention of delayed graft function, or DGF in renal transplant patients. DGF is an early and serious complication of organ transplantation that is characterized by the failure of a transplanted organ to function normally immediately following transplantation.
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
07:52 EDTALXNAlexion says Soliris production not interrupted by FDA facility inspection
Subscribe for More Information
06:31 EDTALXNAlexion initiates multinational registration trial of eculizumab
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use